DWA
DYN icon

Dorsey Wright & Associates’s Dyne Therapeutics DYN Stock Holding History

Dorsey Wright & Associates’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,559
Closed -$18K – 304
2023
Q1 		$18K Sell
1,559
-174
-10% -$2.26K 0.01% 254
2022
Q4 		$20.1K Buy
+1,733
New +$20.1K 0.01% 265

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dorsey Wright & Associates's DYN Position: Q2 2023 in Review

Dorsey Wright & Associates sold out of Dyne Therapeutics (DYN) in Q2 2023, closing a stake of 1,559 shares — an estimated $18K sold.

Dorsey Wright & Associates first reported a position in DYN in Q4 2022 and held it in 2 quarters. The position peaked at $20.1K in Q4 2022. 118 funds tracked by Wall St. Rank hold DYN as of Q2 2023.

  • Dorsey Wright & Associates reported no remaining Dyne Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,559 Dyne Therapeutics shares in Q2 2023, an estimated $18K.
  • Dorsey Wright & Associates first reported a position in Dyne Therapeutics in Q4 2022 and held it in 2 quarters.
  • Dorsey Wright & Associates's Dyne Therapeutics position peaked at $20.1K in Q4 2022.
  • 118 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2023.

Based on Dorsey Wright & Associates's 13F filing for Q2 2023, filed 26 Jul 2023.